Catalent brings together its clinical supply and analytics services
This article was originally published in Scrip
Catalent Pharma Solutions is forming a new business unit, development and clinical services, which will be led by Scott Houlton, who was most recently chief operating officer of development services firm Aptuit.
You may also be interested in...
A group of Belgian and South Korean investors are providing series B funding to support an early-stage clinical study of an off-the-shelf cancer immunotherapy candidate based on an allogeneic plasmacytoid dendritic cell line.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Bayer’s drive to lead a new market opportunity in Europe for histology-independent cancer agents like Vitrakvi has been set back by interim decisions from the UK’s NICE and Germany’s IQWiG, but there is a now a clear pathway to follow.